Holen Sie sich die Stockscreener-App
18.87
6.03%
-1.21
Vorhandelsmarkt:
19.17
0.30
+1.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$20.08
Offen:
$19.76
24-Stunden-Volumen:
6.91M
Relative Volume:
1.50
Marktkapitalisierung:
$3.84B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-7.0149
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-9.89%
1M Leistung:
-50.21%
6M Leistung:
-84.36%
1J Leistung:
-88.26%
1-Tages-Spanne:
$18.70
$19.76
1-Wochen-Bereich:
$18.70
$22.98
52-Wochen-Spanne:
$18.30
$168.31
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
18.87 | 3.84B | 2.23B | -248.39M | -697.55M | -2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.54 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.76 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.51 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta Therapeutics’ SWOT analysis: gene therapy leader faces safety hurdles - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta - Bluefield Daily Telegraph
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat
Sarepta Therapeutics (SRPT): Mizuho Lowers Price Target to $40 | SRPT Stock News - GuruFocus
Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls - Yahoo Finance
Sarepta (SRPT) Faces Price Target Cut Amid Liver Failure Concerns | SRPT Stock News - GuruFocus
TD Cowen downgrades Sarepta Therapeutics to 'hold' - TradingView
Sarepta stock plunges 42% after second fatal liver failure case - Investing.com
Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics - BioSpace
Sarepta (SRPT) Downgraded to Hold with Revised Price Target | SRPT Stock News - GuruFocus
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research… - MarketScreener
Sarepta stock downgraded by TD Cowen on Elevidys approval concerns - Investing.com
Sarepta: TD Cowen downgrades rating, cuts PT on FDA pullback risk for Elevidys - Investing.com
Sarepta Therapeutics (SRPT) Price Target Lowered by Deutsche Ban - GuruFocus
Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback - TipRanks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Second Patient Dies Following Treatment With Sarepta’s DMD Gene Therapy Elevidys - CGTLive®
Sarepta Therapeutics price target lowered to $28 on safety concerns - Investing.com
Sarepta Therapeutics price target lowered to $28 on safety concerns By Investing.com - Investing.com UK
Sarepta Therapeutics (SRPT) PT Lowered to $28 at Evercore ISI - StreetInsider
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm | FinancialContent - FinancialContent
Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation - simplywall.st
Sarepta Therapeutics (SRPT) Downgraded by Goldman Sachs to Neutral | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Downgraded by Morgan Stanley | SRPT Stock News - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Baird | SRPT Stock News - GuruFocus
From $172 to $20: Sarepta’s Spectacular Fall - Trefis
Sarepta Reports Second Death of Patient Using Its Gene Therapy - MSN
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles By Investing.com - Investing.com South Africa
Lilly adds highest Zepbound doses to DTC offering - statnews.com
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | S - GuruFocus
Sarepta Therapeutics (SRPT) Target Price Slashed by Barclays | SRPT Stock News - GuruFocus
Pharmalittle: We're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more - statnews.com
Sarepta Therapeutics’ SWOT analysis: gene therapy pioneer faces safety hurdles - Investing.com India
SRPT BREAKING NEWS: Sarepta Therapeutics, Inc. is being Investigated for Securities Fraud after Second Elevidys Death; Investors with Losses are Notified to Contact BFA Law - Business Wire
SRPT Stock: What’s Happening With Sarepta Therapeutics? - Forbes
Sarepta Therapeutics (SRPT): Analyst Lowers Price Target Amid In - GuruFocus
Sarepta (SRPT) Price Target Slashed, Uncertainty Surrounds Future | SRPT Stock News - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Ami - GuruFocus
Wolfe Research Initiates Sarepta (SRPT) with Neutral Outlook Amid Safety Concerns | SRPT Stock News - GuruFocus
This Week’s CGT News: Investigating the Long-Term Safety of Gene Therapy for Hemophilia B - themedicinemaker.com
2nd death reported in Sarepta gene therapy trial for Duchenne muscular dystrophy - MSN
Biotech pauses trial after second patient death linked to gene therapy - The Washington Post
Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - MSN
Sarepta (SRPT) Faces Price Target Cut Amid Gene Therapy Concerns - GuruFocus
SRPT Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Investors With Significant Losses to Contact the Firm - FinancialContent
Elevidys’ second liver death hits Sarepta, sends DMD ripples - BioWorld MedTech
Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death - insights.citeline.com
Sarepta shares crash as second patient dies after receiving its gene therapy - MSN
Health Care Down as Sarepta Slides -- Health Care Roundup - MarketScreener
Second patient death reported with gene therapy for muscular dystrophy - Hazleton Standard Speaker
Second Teenage Boy Dies From Liver Failure After Sarepta Gene Therapy Treatment - Bloomberg
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sarepta Therapeutics Inc-Aktie (SRPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Barry Richard | Director |
May 13 '25 |
Option Exercise |
19.23 |
20,246 |
389,359 |
2,954,317 |
| Nicaise Claude | Director |
Mar 12 '25 |
Option Exercise |
25.18 |
9,746 |
245,404 |
30,303 |
| Nicaise Claude | Director |
Mar 12 '25 |
Sale |
99.64 |
2,491 |
248,203 |
27,812 |
2.27%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):